| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
70,650,000 |
| Market
Cap: |
3.62(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$38.62 - $89.12 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
89,721 |
159,721 |
184,721 |
409,721 |
| Total Sell Value |
$6,558,882 |
$10,834,513 |
$12,456,407 |
$25,314,056 |
| Total People Sold |
3 |
3 |
3 |
3 |
| Total Sell Transactions |
10 |
12 |
13 |
22 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bolzon Bradley J Phd |
Director |
– • – |
2020-12-10 |
4/A |
AS |
$140.62 |
$4,730,448 |
D/D |
(33,000) |
7,648 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-12-10 |
4 |
AS |
$140.62 |
$4,730,448 |
I/I |
(33,000) |
314,186 |
|
-18% |
|
| Kulkarni Samarth |
Chief Executive Officer |
• • – |
2020-12-10 |
4 |
AS |
$141.17 |
$2,845,782 |
D/D |
(20,000) |
169,189 |
|
-18% |
|
| Kulkarni Samarth |
Chief Executive Officer |
• • – |
2020-12-10 |
4 |
OE |
$1.81 |
$36,200 |
D/D |
20,000 |
189,189 |
|
- |
|
| Kasinger James R. |
General Counsel and Secretary |
• – – |
2020-12-09 |
4 |
OE |
$13.62 |
$299,994 |
D/D |
22,026 |
22,415 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-12-07 |
4 |
S |
$144.39 |
$26,424,505 |
I/I |
(171,004) |
347,186 |
|
23% |
|
| Kulkarni Samarth |
Chief Executive Officer |
• • – |
2020-12-01 |
4 |
D |
$129.58 |
$100,943 |
D/D |
(779) |
169,189 |
|
- |
|
| Novak Rodger |
President |
• • – |
2020-11-30 |
4 |
AS |
$125.00 |
$12,500,000 |
D/D |
(100,000) |
648,007 |
|
-10% |
|
| Novak Rodger |
President |
• • – |
2020-11-30 |
4 |
OE |
$14.00 |
$1,421,500 |
D/D |
100,000 |
698,007 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-10-29 |
4 |
A |
$0.00 |
$0 |
D/D |
18,477 |
40,648 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-10-29 |
4 |
AS |
$0.00 |
$0 |
I/I |
(518,519) |
7,922 |
|
39% |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-10-29 |
4 |
A |
$0.00 |
$0 |
I/I |
105,681 |
105,681 |
|
- |
|
| Novak Rodger |
President |
• • – |
2020-10-09 |
4 |
AS |
$100.00 |
$276,200 |
D/D |
(2,762) |
648,007 |
|
39% |
|
| Novak Rodger |
President |
• • – |
2020-10-09 |
4 |
OE |
$14.43 |
$39,856 |
D/D |
2,762 |
650,769 |
|
- |
|
| Novak Rodger |
President |
• • – |
2020-10-08 |
4 |
AS |
$100.00 |
$2,223,800 |
D/D |
(22,238) |
648,007 |
|
56% |
|
| Novak Rodger |
President |
• • – |
2020-10-08 |
4 |
OE |
$14.43 |
$320,894 |
D/D |
22,238 |
670,245 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
14,780 |
22,171 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-09-22 |
4 |
AS |
$0.00 |
$0 |
I/I |
(414,816) |
10,355 |
|
85% |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-09-22 |
4 |
A |
$0.00 |
$0 |
I/I |
84,544 |
84,544 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-09-18 |
4 |
AS |
$86.87 |
$263,636 |
I/I |
(3,035) |
518,190 |
|
93% |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-09-16 |
4 |
AS |
$86.98 |
$779,777 |
I/I |
(8,965) |
521,225 |
|
96% |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-09-14 |
4 |
AS |
$84.89 |
$98,045 |
I/I |
(1,155) |
530,190 |
|
100% |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-09-10 |
4 |
AS |
$85.03 |
$1,949,996 |
I/I |
(22,845) |
531,345 |
|
130% |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
7,391 |
7,391 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-09-09 |
4 |
AS |
$0.00 |
$0 |
I/I |
(207,408) |
0 |
|
117% |
|
483 Records found
|
|
Page 7 of 20 |
|
|
2.38 (4.44%) 
